|
 
BIOCYTOGEN-B(2315)
Analysis¡G
Biocytogen recently released a positive profit alert, expecting 2025 operating revenue to reach approximately RMB 1.379 billion, representing a year-on-year increase of 40.63%. Net profit attributable to shareholders is projected at RMB 173 million, marking a substantial year-on-year surge of 416.37%. This strong performance is primarily driven by the continued expansion of overseas markets, coupled with the recovery and warming of the domestic biopharmaceutical industry, which has fueled rapid revenue growth. In addition, the Group remains committed to its strategy of innovation-driven performance growth. Through sustained high-intensity R&D investment, it has built robust core technological barriers, enabling the business to maintain stable high gross profit margins, while lean management practices have continuously improved operational efficiency and accelerated the enhancement of profitability.
Biocytogen is a global biotechnology company dedicated to the research and development of novel antibody drugs and the provision of preclinical research services. Based on gene editing technology, it utilizes its proprietary RenMice platform to discover fully human antibodies and has established the Thousand Mice Ten Thousand Antibodies technology platform. Targeting more than 1,000 different targets, the company has created a library of over 1,000,000 fully human antibody sequences for global partnerships. Its sub-brand BioMiceTM currently offers several thousand ready-made animal and cell models, while also providing global clients with preclinical pharmacology, efficacy studies and gene editing services. Headquartered in Beijing, the Group has branch offices in China (Jiangsu Haimen and Shanghai), the United States (Boston, San Francisco and San Diego), Germany (Heidelberg) and other locations.
Biocytogen has secured multiple out-licensing collaborations for its clinical-stage antibody molecules. In the first half of 2025, the company newly signed approximately 80 contracts, representing about 60% growth compared with the same period in 2024. As of 30 June 2025, it had cumulatively signed around 280 cooperation, licensing or transfer agreements for therapeutic antibodies and various clinical assets. It has also entered into RenMice platform licensing and development partnerships with multiple multinational pharmaceutical companies (MNCs) and other collaborators. In February 2026, the Group licensed its B7H3/PTK7 ADC candidate IDE034 to IDEAYA. Following the enrolment of the first patient in the Phase 1 clinical trial, IDEAYA will pay the Group a US$5 million milestone payment, with the total potential value of the collaboration reaching up to US$406.5 million. As the number of licensed projects continues to increase and clinical progress advances, the performance elasticity of the antibody development business is expected to accelerate, unlocking substantial long-term growth potential.(I do not hold the above stock).
Strategy¡G
Buy-in Price: $50.50, Target Price: $56.00, Cut Loss Price: $48.00
| 
SHANXI COAL(600546)
Analysis¡G
The Company is a SOE of Shanxi Province, and currently mainly engages in coal production, trade, and sales business. The performance is mainly driven by the coal production sector. In the future, the Company plans to arrange the production and manufacturing of heterojunction batteries, aiming to optimize the industrial structure and create a dual wheel driven development model of coal production and new Energy development on the basis of doing a good job in the main industry of coal. In the first three quarters of 2025, revenue reached RMB 15.332 billion yuan, down 30.20% yoy, while net profit attributable to the parent company stood at 1.046 billion yuan, a decrease of 49.74%. The primary factor was the contraction in trading coal business (sales volume dropped 28.5% yoy), though self-produced coal operations demonstrated resilience, achieving a gross margin of 50.2%. As the sole entity in Shanxi Province with coal import and export qualifications, overseas revenue accounted for 33.5% of total revenue, poised to benefit from Indonesia's export contraction and rising international coal prices. The company pledged a dividend payout ratio of no less than 60% from 2024 to 2026, highlighting its long-term investment value.
Strategy¡G
Buy-in Price: RMB12.15, Target Price: RMB14.20, Cut Loss Price: RMB11.00
|
|
JOYSON Electronics (600699 CH) ¡V Expanding into Robotics to Build a Second Growth Curve
Company ProfileAs a leading global supplier in automotive electronics and automotive safety, Joyson Electronics provides one-stop solutions in key technology areas of intelligent electric vehicles to global OEMs. The Company's business is divided into two major segments: automotive electronics and automotive safety. The automotive electronics segment mainly includes intelligent cockpit, intelligent connectivity, intelligent driving and new energy management, while the automotive safety segment mainly includes products related to seatbelts, airbags, intelligent steering wheels and integrated safety solutions. In 2025, the Company strategically extended into the upstream and downstream of the robotics industry chain, newly positioning itself as "Automotive + Robotics Tier1" and actively building a second growth curve. Investment SummaryThe Company Released Its 2025 Earnings Forecast: Core Profit up 17%It is expected that in 2025 the Company will realise net profit attributable to owners of the parent company of approximately RMB1.35 billion (RMB, the same below), up 40.56% yoy; net profit attributable to the parent company excluding non-recurring items is expected to be approximately RMB1.5 billion, up approximately 17.02% yoy. The difference between the two is mainly due to non-recurring losses of approximately RMB160 million arising from the transfer of the weighing apparatus business by the Company's listed subsidiary Guangdong Xiangshan Weighing Apparatus Group Co., Ltd. (002870.CH), as well as the optimisation and disposal of certain overseas factories. The Company attributes the growth in results to the gradual effectiveness of various profitability improvement and business integration measures implemented across global business regions in 2025, as well as the continued recovery in profitability of overseas operations. Profitability of Core Businesses Continued to ImproveThrough optimising and integrating its global operations, particularly achieving notable results in reducing global raw material costs and improving operational efficiency, the Company has significantly enhanced its operating performance and profitability. The Company's overall gross margin increased from 11.1% in 2022 to 14.5% in 2023, further rising to 16.2% in 2024, and continued to increase to 18.31% as of the third quarter of 2025. From a regional perspective, overseas markets have focused on continuously reducing raw material costs by introducing Chinese suppliers and optimising procurement prices from existing suppliers. Meanwhile, the Company's global operational improvement team has continued to optimise and enhance OEE (Overall Equipment Effectiveness) at overseas factories, while adjusting and relocating production capacity from high-cost countries/regions to low-cost countries/regions, thereby steadily driving gross margin improvement. In particular, cost improvement measures in the European region were implemented earlier and achieved significant gross margin enhancement during the reporting period. Cost improvement measures in the Americas were implemented relatively later, and gross margin is expected to improve correspondingly in the future, with profitability continuing to strengthen. Sufficient Orders on Hand with Sustainable Growth Potential in Core BusinessesIn the third quarter of 2025, the Company secured new orders with a total full lifecycle amount of approximately RMB40.2 billion. In the first three quarters, the Company's cumulative global newly secured orders reached approximately RMB71.4 billion in total full lifecycle amount, of which approximately RMB39.6 billion was from the automotive safety segment and approximately RMB31.8 billion was from the automotive electronics segment. According to Frost & Sullivan, in 2024 the Company's market share in automotive safety products ranked second globally, with global and China market shares of 22.9% and 26.1%, respectively. It is estimated that by 2029, the global and domestic market sizes of the automotive passive safety industry will grow to RMB213.6 billion and RMB49.7 billion, respectively, representing CAGR of 5.4% and 7.8%, respectively, from 2025. It is further expected that by 2029, the global and China automotive electronics market sizes will reach RMB3,330.3 billion and RMB1,892.6 billion, respectively, representing CAGR of 5.8% and 9.4%, respectively, from 2025. In H1 2025, the automotive safety and automotive electronics segments accounted for 62.53% and 27.53% of revenue, respectively. As the Company firmly drives development through technological innovation in automotive electronics, maintaining intensive R&D investment in intelligent cockpit, intelligent driving, intelligent connectivity, vehicle-road-cloud coordination and high-voltage fast charging for new energy vehicles, it ensures sustained leadership in key technology areas and possesses long-term growth potential. Expanding into Robotics to Build a Second Growth CurveAccording to Frost & Sullivan, the humanoid robot market size is expected to surge from USD2.3 billion in 2025 to USD12.9 billion in 2029, representing a CAGR of 54.4%. The Company has established strategic partnerships with several leading domestic and international robotics companies and has successfully launched a series of products, including AI-empowered robot head assemblies, integrated robot domain controllers and next-generation robot energy management solutions. Investment ThesisAs a leading enterprise in automotive safety and automotive intelligence, the Company possesses strong R&D capabilities. Its automotive-related businesses are expected to continue benefiting from the global trends of vehicle electrification and intelligence, while its expansion into the humanoid robotics field is poised to open up a second growth curve.
We expect Joyson's EPS for 2025-2027 to be 0.88/1.19/1.43 yuan. We revised the target price of RMB 33.4 equivalent to 37.8/28.0/23.4x E P/E 2025-2027 and assign Buy ratings. (Closing price as at 2 March) 
RiskOperating collision in Joyson's M&A
Worse-than-expected downstream demand Financials
(Closing price as at 2 March)
Source: PSR Download PDF version...
| Recommendation on 10-3-2026 | | Recommendation | BUY (Maintain) | | Price on Recommendation Date | $ 27.370 | | Suggested purchase price | N/A | | Target Price | $ 33.400 |
| |
|
|
|
|
| Stock Code |
H share
Price |
A share
Price |
H share
discount |
| | | |
|
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.
If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.
ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C
Copyright(C) 2026 Phillip Securities (HK) Ltd. All Rights Reserved.
|
